Fulcrum Therapeutics Inc (FULC) financials
Fulcrum Therapeutics revenue and earnings by year
Fulcrum Therapeutics's revenue was $80.0 million in the fiscal year to December 31, 2024, up 2752.0% from the year before. Net income was -$9.72 million, -12.2% of revenue. Since the fiscal year to December 31, 2020, revenue has grown 73.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Revenue | 80 | 3 | 6 | 19 | 9 |
| Revenue growth | 2752.0% | -55.8% | -66.9% | 117.2% | — |
| Operating income | -22 | -111 | -113 | -81 | -72 |
| Operating margin | -27.4% | -3945.2% | -1774.9% | -423.0% | -811.6% |
| Net income | -10 | -97 | -110 | -81 | -71 |
| Net margin | -12.2% | -3470.1% | -1732.4% | -421.9% | -802.7% |
| Diluted EPS | -$0.16 | -$1.59 | -$2.44 | -$2.29 | -$2.80 |
| Free cash flow | -2 | -91 | -99 | -80 | -55 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open FULC in Markets.
See also: FULC returns
No forecast, no recommendation. This page describes Fulcrum Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.